The Advocate's Brief — SAMPLE

Condition Overview

Basal Cell Carcinoma (BCC) is the most common form of skin cancer, typically managed through surgical excision with high cure rates. However, Sarah's case represents a statistically significant deviation from expected outcomes. With 6 recurrences over 8 years despite clear surgical margins in each procedure, her case falls outside the standard recurrence probability of 1-5% for adequately excised BCC. The recurring nature across both treated and untreated sites suggests potential underlying factors that standard-of-care protocols do not adequately address, including possible field cancerization, genetic predisposition, or immune-mediated vulnerability.

Recurrence History & Pattern Analysis

Sarah's first BCC was diagnosed in March 2018 on the left side of her nose. Since then, she has experienced 5 additional recurrences with a progressively shortening interval between events, suggesting an accelerating disease pattern rather than isolated incidents.

• Recurrence interval has shortened from 18 months (2018-2019) to approximately 8 months (2025-2026), indicating a possible acceleration pattern that warrants proactive rather than reactive management.
• Three of six recurrences occurred at or immediately adjacent to previously treated surgical sites, despite pathology-confirmed clear margins, suggesting subclinical disease extension beyond visible borders.
• Two new primary sites (left ear and right temple) have developed in areas with high cumulative UV exposure, consistent with field cancerization theory and potentially requiring a broader preventive strategy rather than site-by-site treatment.

Treatment History

Sarah has undergone a total of 8 procedures and 2 courses of topical therapy across 8 years. Each intervention was performed according to standard-of-care guidelines, yet the recurrence pattern persists.

Failed & Insufficient Protocols

Standard surgical excision proved insufficient for Sarah's case, with 2 of 2 excision sites recurring within 12 months despite clear margins. Mohs surgery, considered the gold standard for BCC, achieved clear margins in all 4 procedures but failed to prevent recurrence at 3 of 4 sites. Topical Imiquimod therapy was abandoned after 6 weeks due to a severe inflammatory response that required medical intervention. Cryotherapy, attempted once on a superficial lesion, resulted in incomplete clearance and subsequent progression to a deeper nodular BCC within 5 months. The cumulative evidence demonstrates that Sarah's BCC does not respond predictably to standard-of-care interventions, and a continuation of the same approach without modification constitutes an insufficient treatment strategy for her specific pathology.

Current Status & Medications

Sarah is currently presenting with a newly identified suspicious lesion on the right temple, detected during routine self-examination in February 2026. Biopsy is pending at the upcoming appointment. She maintains a rigorous daily sun protection regimen including SPF 50+ broad-spectrum sunscreen, protective clothing, and monthly full-body self-examinations. Current supplements include Vitamin D3 (2000 IU daily) due to limited sun exposure. She is not currently on any prescription medications related to her BCC history. Her most recent dermatology follow-up was December 2025, at which no suspicious lesions were identified, placing the interval of new lesion development at approximately 2 months.

Questions for This Appointment

1. Given 6 recurrences despite clear surgical margins over 8 years, should we consider genetic testing (such as PTCH1 mutation screening for Gorlin Syndrome) to rule out hereditary predisposition as a driver of this recurrence pattern?
2. Would Vismodegib (Erivedge) or another Hedgehog pathway inhibitor be appropriate as a chemoprevention strategy, given the accelerating recurrence interval and multiple failed surgical interventions?
3. Should we pursue photodynamic therapy (PDT) as a field treatment for the broader areas of sun-damaged skin on the face rather than continuing to treat individual lesions reactively?
4. At what point does the pattern of recurrence at Mohs-cleared sites justify referral to a multidisciplinary tumor board or dermatologic oncology specialist for a more aggressive or experimental approach?
5. Is there clinical value in requesting immunohistochemistry or molecular profiling of the next biopsy specimen to identify whether these recurrent BCCs share specific mutations that could inform targeted therapy options?

Patient Advocacy Statement